Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t think it will get to the pink sheets. If we somehow pull off the crime of the century and get a substantial ($20-30 mil+) from some Hail Mary, we will be around to live an extra few quarters. Nothing in the next 3 to 6 months max, we’re toast imo. Lots of singing fat ladies will be chasing us around with forks.
Hey Midas. You seem to have lost some faith in this companies chances of success. Am I reading that right? You were always one of the stalwarts for these guys. And have endured a lot from sticking around with this company for many years like some others of us have. Just curious that’s all.
Was looking over the maximum walking distance from our fresh data again. I did see the 300-300 dose did have a mwd change of 32.7% from baseline. But if you look at placebo-placebo, they seemed to have a change of around 26%. I’m the US graph there’s a little bigger difference, around 37% compared to around 10%. Am I reading this wrong or is the difference between treated and placebo only 7-17%.
Now being the curious type, I wondered what the actual distance was. Upon having another look at the trial design, it gave time, not distance. But at least we get a measurement to relate it to.
Seems the inclusion criteria was a mwd of 1 to 10 minutes. So the 300-300 group went from 1 to 10 minutes to 1.33 to 13.3 minutes. Or in US up to 1.37 to 13.7 vs placebo’s jump to 1.1 to 11 minutes. An improvement for sure, but put in terms of time, really does not seem too beneficial to me. Certainly no reason for an insurance company to pay.
Now let’s go the the “less signal less potential benefit” claim from Spidey. They said “therefore for the majority of the time when these patients are not pushing their bodies, the help signals will likely be reduced”
I’m sorry but these patients had a mwd of anywhere from 1 to 10 minutes. I would think the pain from pretty much any daily activity from something as simple as normal everyday living like going to the washroom, would be there more often than not. This was not a pain free maximum walking distance. You assume these patients are “not pushing their bodies”. I live with certain pains pretty much every day. Some days pretty severe. I still do the same activities/work no matter how bad it feels. So that assumption is pretty weak.
But here is my positive for the day and Spidey pointed it out. There were no major amputations in any of the treated groups. If we could have seen p value on that, would have been much better. But at least it is a step in the positive. Wouldn’t want anyone to think I’m all doom and gloom. These are the minuscule things I find positive. Unfortunately not too many of them.
One thing that was never covered. How are they going to fund this company for the likely 2 or 3 more years at absolute best, before we have numbers from the first half. That IS, the million dollar question. All but one of their CLI outcome measures have an up to 36 month. That’s how we were able to get such a small number of patients for the phase 3 right. So conveniently and as overly optimistic anybody could be, the estimated completion date is...you guessed it...36 months.
Doesn’t infuriate me in the least. Nor surprise me. Not here for the thank you’s or anything else except to shed some light on this 2 bit company that has over promised and way under delivered for so many agonizing years.
I wasn’t being serious either. But my apologies for not saying thank you so thank you. I have spent more hours researching absolutely everything about this company. Way too much time. Something has been wrong with this company for a very long time. Pretty much everything with regards to how this company is run sucks imo.
These guys have made numerous missteps over the years. Change in directions, who they hire, how many they hire, premature bonuses, manufacturing most likely and the list goes on and in. I point ALL of these things referencing everything I find from company themselves, competitors, anything and everything. I think I draw pretty compelling arguments. Nobody even tries to refute what I bring up with anything substantial. Only thing now is analysts and tutes. Quite the argument don’t you think.
I’m sorry but if the market themselves thought anything of our results, I might agree with something you said. With our price only moving in the down direction, I think my “conclusions” may be more applicable.
Only thing I ever get from anything I state is “I’m good with them”.
To sit there and think we could even get anything close to that is laughable at best. If a big pharma wanted anything we have as of yet, they would get it. Don’t think they would be able to attempt a hostile takeover for that same $800 mil? Management does not have enough shares to stop something like that from happening. They could get everything for that price. But then again, they wouldn’t want all the dead wood.
I’m sure a vast majority of shareholders would take a 5 to 10 bagger in a heartbeat. Heck even company employees would probably want that. Vote the goons out if they didn’t accept. Would be an easy thing for them to accomplish imo. Problem is, nobody wants them imo.
Even Zami’s relatively small golden parachute clause if change of ownership happens shows what he thinks of the possibilities of that happening. With such a small cut, almost seems like they’re trying to entice that.
One clear thing to remember about these guys. Kaki stayed don’t bet against Pluristem. Why haven’t they bet ON Pluristem with their own cash? They could have easily put in automatic buys to avoid insider trading. They’ve had a couple years without any earth shattering news no? But they would rather just play with their free shares. Less risky that way. Now that’s confidence!!!
No I’m pretty sure it’s the analysis from professionals that is causing the drop.
Not missing you, just didn’t want to be Houdini’d like usual. I can see why it took so long to reply. That’s quite the spin on a mediocre at best, result. You can try to throw in all the technical terms you want, many based on your own opininions, especially the “less signals, less potential” claims.
I’m sorry but the whole reason for the revascularization or amputation is reduced blood low from the clogged up arteries. I would think having revascularization performed, it’s pretty serious already.
The company did enrol the 150 patients, then put out this statement as well.
“Pluristem has expanded the trial to enroll 20 additional patients to be randomized in order to preserve the study’s original design to administer two injections to each of 150 patients. Twenty of the 150 patients originally enrolled did not complete the trial with two injections.”
https://globenewswire.com/news-release/2016/05/16/840121/0/en/Pluristem-Completes-Enrollment-of-150-Patients-in-Phase-II-Intermittent-Claudication-Trial.html
The question I raised was why are those 20 patients that only took their one dose still in there? Did they just move them to they just move them to a different cohort? That’s what I find suspect. No other cohort had a single injection only, so where’d they put them then? Then the addition of 2 donors. Like I said, smells a little fishy. Did they even do that because of what they said, or possibly for some other reason. That’s what I wonder
Even look at their own conclusions. Nothing really jumps out at you. MWD yes was improved with statistical significance. Other than that, not much. Not sure what insurance company will pay for someone to walk a greater distance. We don’t even see what distance they’re talking about. Did it go from 1 mile to a mile and a half? Or 10 feet to 15 feet. You get my drift.
I’m not trying to pretend I fully understand all of the results and their implications. But the points I made weren’t changed with your post. More importantly, it doesn’t seem the street and all the truly qualified people they employ for their research does either.
It was pointed out today what can happen with a successful phase 2 study from Arena can do. When will our price jump from our phase 2 happen?
Wow it almost looks like they’re thinking of trying to market their 75L bioreactor. Another clue to the reason for the recent TF collaboration? They stuck at 75L? Funny no mention of commercial scale, only pre-clinical and and clinical development. Imagine if they did it 10 years ago when this was in its infancy. It’s not like there’s any competition in this space is there?
“Conduct a cost-benefit analysis of the differences between proactive automation for scale and reactive scalability
Create a manufacturing process that is flexible enough to deliver lean production across pre-clinical and clinical development
Adopt best-in-class technology to assist in in-house manufacturing rather than outsourcing your production”
Please point me to the specifics you call nonsensical???????????????????????????? Let me guess. All of it. LMBO!!! You are a party of one. Even others don’t come to your defense.
Sure it is Chachi. Couldn’t answer a one. Go figure. Pretty sad synopsis of our beloved company. Highly doubt we will see any attempt to refute what I stated. How could anyone. So don’t worry, you’re not alone in denial. All coming down to Hope and Prayer. Hey maybe that’s what Ark relies on. LMBO!!!
Just basing my call on the fact that any TA call that has ever been made by one poster on this board, the exact opposite of what the interpretation of their TA said. Nothing more. But 100% accurate so far. Maybe this time will be the first win. Let Hope and Pray.
“Unsupported opinions”
Funny I seem to recall using many facts to back up my claims. Most coming from statements from the company (or lack of), quarterlies, Pluristem website, presentations. I’ll go over just a few of them and number them. That way we can see all the rebuttals from each specific one.
1 - Management. Did anyone find any top executives from any big pharma on Plusitem’s about page? Does the jump from R&D research analyst at Teva to VP of Development at Pluristem count? Or a manager at Teva to VP of Quality Assurance? Top executives from big pharma don’t really matter I guess. It’s not like they would have any connections to former employers anyways, that could lead to a potential partnership or something as useless as that.
2 - Financials. My calculations from their filings were pretty close to reality don’t you think? I did take off Accounts Payable on their final cash total, unlike our accountant turned co-CEO. And I guess I should have taken accounting courses as them I would have understood the common term appearing on all financial reports. “Additional resources”. Or how much direct funding still available from the once touted, $27 million in funding from previous presentations this year.
3 - Bonuses. Yes a CFO from Brainstorm getting 25k shares as a bonus, doesn’t compare to the 388k ours has gotten since May of 2017. Or the millions of share our 2 twins have received. Or the nearly half mil most of our long term board member are up to.
4 - Conflicts. Our great big buy ratings have no conflicts here at all. Even one was pointed out just today. B Riley has a quarter of a million shares and they put out a buy rating. No conflict there. Irrelevant. LMBO!!! That’s not even the reason for the buy imo. It’s a piece of the lucrative raise pie they’re after.
Or no conflicts from researchers or scientists going on a world tour promoting our amazing IC results. How much funding have any of them received from either Pluristem themselves, or grants. A lions share of $8 million in grants goes a long way to pay all the involved employees of their respective organizations.
5 - IC results. Now here I may have taken a little leeway as these study results are beyond my scope of knowledge to an extent. But when I see revascularization results pretty similar to the placebo, it’s not hard to make assumptions. Or a cohort of 11 patients in the 2 donor source having zero events, doesn’t bring around reassurance. Funny no p value was given to that cohort. Even the other cohorts gave p values that were statistically insignificant. I would imagine the 2 donor one would have been close to 1.
And the best part is what Pluristem touts from this IC trial. “Confirms dosing regimen for CLI trial”. Or confirms “safety”. Wow, I wonder how much that IC trial cost for those stellar confirmations. Did none of what they got from IC trial indicate any reduced risk of amputation, the main goal of CLI trial?
But again, I’m waiting for experts here like Spideyboy to weigh in on this topic.
6 - Lack of transparency. Do we ever get a single clear statement on any news release. We get enough just to keep us guessing. Worded in ways that can be taken 2 completely different ways. Have we ever seen them give enrolment numbers on any of their trials. Aside from IC after painstakingly awaiting years for IC. Have they ever made milestones? Why did they take them all away now? Where’s our stockpiling agreement promised in 2017? Or our start date of pivotal ARS trial from 2017, moved to 2H18, now just updated to any time in 2019? Our interim “results” promised for 2h17, just came out with a whopping 3 patients. Amazing!!!
So you see my opinions are based on what I find. Feel free to counter on any or all of them. That goes for anyone. Even when the “charts” are showing down, the one aspect of someone’s “investment” decision, they are still Believing analysts and their recommendations. Even if they haven’t come true for over a decade. Let’s Hope and Pray the tutes are right for once this time. It’s pretty much all we got left.
Be careful what I post? Is that another threat? Please point to which past post thou speaks of. Hey, are you a “twin”?
It’s just one big bidding war, over 10 years long, all under the radar of everyone. All vying for a shot at one of the many patents that could be sold off at auction to the highest bidder. Companies unlucky enough to be owed money from Pluristem, will want to get a few nickels back after all. Even our accountant doesn’t want to mention them.
The big question is, when does the cash saving contingency plan come into play? What effect would something like that have on our price. Fingers crossed!!!
Don’t look now but we are getting ever so close to the sub $1.15 close. Should be downhill from there right. But if we look historically at any of the calls made here, we will most likely move up. A contrarian indicator right here on our board. LMBO!!!
Wow even if the 40 tutes were equal in the 5.8 million shares they own, you’d be looking at 145K each. Doesn’t ARK have most of those shares? Must make the other 39 of them have a huuuuuuge position. I’m in!!! I belieb!!! Tute ownership IS a good sign...to Hope and Pray.
Instead of complaining and quoting, how come you never once try to counter any of the many claims, WITH FACTS, that are brought up? Too hard of a task? Crying while thinking about the several big 25k blocks of $2 shares is much easier. And painful. LMBO!!!
LMBO!!! Did I not just state that!!!
Wonder how many of the 40 tutes are holding 10k or less shares? Ark’s total portfolio equals $3.3 billion. Half a mil or so is quite substantial. But beware of these big guns in our tiny little stock. What did Sabby do for us? And how many vying for the potential upcoming raise have taken a small stake?
Funny how one who said tute investments is not a reason to buy, has now changed their tune. The one that’s said “hope I’m right for a change” is now a full fledged belieber. Sounds more and more like Hope and Prayer to me.
The clarity that comes from BCLI was a big point in my argument. At least by focusing on one product, owned or licenced, they will be able to make it to the finish line with the cash they have already. How are we going to find it, with 2 phase 3’s running, among other things? And now PLX-Immune. Seems like not hiring 180 employees have helped them to do it.
How are they able to move through their trial with relative ease, while we take 5 1/5 years to enrol 170 patients in IC? They’re on pace for just over a year and a half for their 200 patient trial.
Go and look where most of their top personnel have come from. VP’s of big pharma. Have a look at ours. Try to find even one with any sort of top big pharma positions. We have 3 that came from Elbit Vision Systems (our great co-ceo’s Included), one that came from Immuron (diarrhea prevention company trading at 28 cents), a coo from Depochem Amgel (industrial raw materials supplier), a coo from Excellenz Bioscienses (???) one a manager at Teva, and an analytical researcher from Teva. And almost forgot, a doctor
Quite the pedigree don’t you think? Won’t even go into our board. Wonder how close all of these goons are to making the $300k that Brainstorm paid for a VP from Novartis.
So yes their price is sitting around $3. They went up to over $5 from these levels this year. When have we ever seen a $2 swing to the upside? At least there’s some significant gains to be made while waiting. Not dead money like ours. May get a 7% gain if you time the swings perfectly with us. So it is a little more than just price or transparency between the 2 of them. It’s night and day like I said.
Everyone should go take a look at Brainstorm. Just to take a look at how a different Israeli company is run. It’s like night and day.
They released their quarterly, gave a cc, a shareholder update, updated enrolment numbers, guidance on trial completion dates, cash on hand TAKING ACCOUNTS PAYABLES out of their actual cash they state, talk of new hires from senior big pharma positions. Hired Arturo Araya, VP of Novartis to be chief commercial officer for $300k a year. Quite the bargain for the experience don’t you think. Gave CFO 25k rsu’s. Pretty reasonable don’t you think.
Started phase 3 ALS trial August 2017, and are on pace to get fully enrolled mid 2019. Company is FULLY FUNDED to completion of this trial.
It’s quite remarkable. They focused on a single product, put all resources towards it, kept number of employees to a tiny fraction of what Pluristem did. Managed to find a company to manufacture cells for them, and will be able to upon commercialization.
We unfortunately, have 2 goons. One who decided to waste 2 years clinical developmental time to build out manufacturing for what? So we could manufacture our own cells for our trials only? Wonder if the cost of 500 square meter gmp clean room was worth the money to build. The years of rent or the cost of having employees to operate it, maintain it, inspections, and everything else associated with something like this.
Wonder how much all the directional changes have cost us. Preeclampsia, Duschennes, MS, Beurgers, steering committees, thawing devices. Or the 180 employees, consultants, office furniture, computers, phones, office rent.
It truly is a joke what we have here. It’s sad and our price is the result of having inexperienced people pretty much through all the senior positions and definitely all the board.
But we should all just be “ok with them”
Where’d you go Spideyboy?
You were anxiously awaiting additional data, yet we get silence. Any thoughts on your company presentation, secondary outcome measure, revascularization? What did you think of that data set? Was it statistically significant?
Placebo 50 patients with 6 revascular events
300m + placebo dose 37 patients with 6 revasular events
150m x 2 dose 37 patients with 7 revascular events
300m x 2 dose 48 patients with 3 revascular events
300m x 2 dose from 2 donors. 11 patients with 0 revascular events.
Now they say this on their presentation. “Reduced revascularization risk by 49% in the main efficacy group at week 65”. They took the 2 arms of 300m x 2 and used that against placebo? Funny how they don’t show the p value on that one.
What seems strange is why the 2 donor 300m x 2 group was not one of the 4 groups listed in the trial design. It didn’t even make it to their presentation. No simple search on the internet could find it either.
Now we were told 20 of the patients didn’t receive their second dose, and that’s why the trial was expanded from 150 to 170. Now why would they all be included still. Maybe this is normal, I don’t know. Plus could they have added the 2 donor arm after the original 150 were complete? Don’t ever recall anything mentioning 2 donors ever until after the fact. Something just doesn’t add up imo.
Now with revascularization rate seeming to be a dud, what do you think the time to amputation or AFS results will be with the tougher nut, CLI? None of the previous 2 small CLI trials had statistical significance. Just think the challenge to replicate the outcome with a larger group is quite task. You would think of our product
But maybe you will set me straight.
And where’s the link showing us at that conference. Or is management going incognito, to make it look like they’re being frugal. We are in London those days, at the Cell and Gene Therapy Manufacturimg conference. We going to crash that event?
Averaging down while we had a fast track Japanese approved trial design (with only 75 patients), new Sosei venture and Chinese investment of $30 million. One even became binding remember. Seemed like a good call back then and turned out to be ok for me. But whatever happened to the Japanese IC fast track, Sosei and Chinese investment? Once those things failed, is when I started looking a little deeper into this company and found an incredible stench with what I found.
With any luck, we will get back under a buck and you too, can have a great chance to average down for cheap. Fingers crossed!!!
Someone getting a little HANGRY!!! Fruits and veggies aren’t that filling.
Funny I never bought in near the highs. In fact was able to average down sub $1 that allowed me to sell at a small profit. Now I gamble with leveraged, cheap options. Yes many believed what management spewed many years ago that in hindsight, were misleading to be polite. Before the missed milestones became the MO of the company. Don’t think any of the long timers would have added in the last 3 years or so, because of managements ability to accomplish little in all these years. Direct correlation to their lack of experience.
To buy since then, in full light of all of this, takes risk to a new level. Raise your hands if you bought recently!!! I Hope and Pray people that did aren’t down “too much”. Would hate to see the ones accounts who bought during the pump last year. But remember, anything under $2 is a steal!!!
Yes we have now seen tremendous “progress” on the diabetic front. Seems like I must have missed that term completely on the new “updated results”.
Guess we should leave all that all to the “pros”. They’re loving the latest news. Only down 2 pennies so far on this great progress. Heck any day now we may see a Strong Buy recommendation coming!!! Fingers crossed!!!
With vitamin c down 25%
Why don’t you find something to explain our approximately 40% haircut in the last 13 months.
We have found a replacement for vitamin C to reduce CRP levels. To the moon!!!
“Among participants with CRP indicative of elevated cardiovascular risk (> or =1.0 mg/L), vitamin C reduced the median CRP by 25.3% vs placebo (p=0.02)”
https://www.ncbi.nlm.nih.gov/m/pubmed/18952164/
Maybe ARK will have to report a 5% stake soon!!! Another Sabby in the making. Fingers crossed!!!
Gotta love the financial update on the presentation. Still doesn’t include liability side of the equation. They do state the additional “resources” via grant money left of approximately $8 million. Seeing that they’ve burned through most of the direct cash, I would assume that’s what’s left of ALL grant money including amounts for other parties. That should see them through the half way point in CLI shouldn’t it? Guess that’s why it didn’t appear on the financials.
And I did not take into a missed grant from earlier in 2018. Indiana University did receive $2.5 mil to study plx-r18 in other populations. We will get reimbursed for cost of supplying product. Wonder if twins and board got cut of that non dilutive grant too?
Look at pretty much anytime throughout the history of the company, the only constant is pushing timelines forward as each one is missed. Time and time again for many of them. Your 2019 observation does allow for 13+ months out. Now that’s what I call progress. At least they won’t have to push it forward until then. Wonder when we will see the stockpiling in 2017
Where oh where did PLX Immune go? LMBO. But but but, someone was building a new facility or expanding one for this reason alone weren’t they? I guess diabetes is the latest new direction. LMBO
Wow if you look at Zami’s shareholder update from February, you would have thought it was a done deal for the 2h18. But it’s probably a done deal now.
http://www.pluristem.com/wp-content/uploads/2018/02/Q2-2018-Highlights-Release-FINAL.pdf
“We expect to collect the complementary data during the first half of 2018 and to clear the pivotal study protocol and funding during the second half of 2018. “
How bout if two trees are posting in a forest, does anybody hear. LMBOx200,000-190,000. Margined the extra shares.
Yes always trying desperately to connect fictitious dots.
I’ve been saying for a long time that the US government is not going to pay a ton for anything from pluristem. The twins bargained hard to get them to pay for the trials, while competition was getting between $50 mil to $300 mil funding to develop their ARS product. If they got $10 mil for this pivotal trial to start, that would be a shock. At this point the twins should just get the damn thing going.
There is obvious a need, and a desire to move this thing along. Never had a holdup like this before. Only difference is they’re trying to get money for it, something they would have gotten from day one if they knew what they were doing. Honestly I wouldn’t be surprised if another company, say from the US, to take it right from underneath them. Others using placental cells, msc’s everything and anything now. Everyone knows they’re desperate, except maybe a few on this board. The silence on this topic from the company sure does smell rotten. Just like their silence on enrolment numbers. Just like their silence on everything for that matter. Rotten to the core. Except PLX Immune. Go Pluristem!!!
Management probably believe the analysts ratings and tute holdings as a sign of being a great company. Unfortunately they are just complete and utter IDIOTS if they were to do that. Don’t think anyone in their right mind would agree with that.
Great that management makes everyone search to find anything out about this company. Don’t even have the balls to say it in an update
Study started Feb 8/17. In all this time up to July 2018 and they have had 3 go through completely, and 3 yet to finish their one year follow up. Wow really steaming along full speed on this one eh? At this rate, we should be done this phase one sometime in 2022.
This is a great find. Shows why they aren’t doing any update on enrolment numbers in anything. It’s embarrasing how slow anything progresses. It’s unbelievable really. Oh the IC trial was done by an incompetent CRO. What’s the excuse this time? They have zero clue on anything and this is just more proof of that. Oh but that’s HCT. CLI probably has at least 6 enrolled by now.
Why are they releasing these early numbers from a whopping 3 people. DESPERATION!!! Throwing anything and everything out there hoping something sticks. This company truly is the laughing stock of the biotech industry. Should be part of a poster. How Not To Run A Biotech Company. With the twins mug shots right there front and center for everyone to laugh at.
Updated Financials.
Kaki has made this job easier with the big update he made. But I’ll expand on his numbers since the accountant wanted to conveniently omit some important info regarding cash they have access to.
Kaki’s all cash and grant money remaining. $22.5 mil.
Liabilities. $7.4 mil
Leaving out another $2 mil in long term liabilities.
Grand total $15.1 mil remaining as of Sept 30th. Here we are almost half way through the next quarter, so how much now. Just using Kaki’s statement of $8.5 mil used last quarter, it’s easy to see we are a long way from having enough to make it to 2020.
Yes cost cutting measures have been put into place. Question is, when does the cash saving contingency plan kick in? They going to wait until under $10 mil...$5 mil?
They are in quite a predicament, that’s for sure. So bad that Kaki has to spew some garbage of an additional $7.5 mil in “resources”. What the hell is that? Is this a new financial term I’m not aware of? Kaki utilizing accounting liberties. Did I miss these resources in their filing? It’s one thing. DESPERATE!!!!
Unfortunately I don’t think the job cuts that have/are coming doesn’t make employees at Pluristem ecstatic. And any long position in this stock surely doesn’t make anyone ecstatic. Only ones who are truly ecstatic are the twins and how much they’ve milked from shareholders out of over all these years.
Only good thing about all of this is we will see soon enough if company will survive, or if the lights will go out.
Does one even read what they post. Yet again, like ALWAYS, nothing to do with Pluristem. Useless. Just burying posts is all that’s being done.
One reason for the expedited expansion is the work done for the National Cancer Institute. The work is a competitive bid that Thermo Fisher Scientific must apply for every five years, said Niveen Mulholland, director of government operations for Fisher BioServices. The company has held the contract for 32 years.
The company needed to be able to support a 25 percent increase in growth each year as part of the contract, and the new facility will allow them to do so, Mulholland said.
Hey Spidey,
Did they announce any of the additional endpoints you were looking for. You know, the ones from presentations? Seems pretty strange not a mention of a single one you mentioned don’t ya think? A simple search found them, but not a peep about them.
Now you never did answer my question (go figure) on if the FDA would allow data from non listed outcome measures to be used or not.
Now another question. If they weren’t listed officially in the site, are they required to show the results? Could they have not listed them in the trial design, in order to get the results off the record so to speak. So if results were irrelevant or bad, no need to state them. I would imagine if they were listed on the design, they would have to be released either way. Maybe that’s the risk of listing everything under the sun.
Just curious what reasoning could be behind the missing measures. The additional data touted by management, proudly preached by the new frequent flyer also paid by company for services rendered, the one the only, Norbert Weiss, seems to be nothing more than a rehash of what was already announced in top line data, but with more technical jargon attached.
Maybe the additional outcome measures you found by a simple search will be included, if they announce it via a press release come Tuesday. Otherwise, the silence regrading these additional outcome measures will speak volumes on why they weren’t included in the trial design. Or were kept silent by the company. All IMO of course.
PLX IMMUNE is in its infancy at best. Will get nowhere. A feeble attempt by management to boost share price via a cancer treatment. There is absolutely no way they are going to start a new product and beat anyone to the finish line. No way. Any known product such as ours, will be tried by others, with the deep pockets and know how, to beat us on anything in the future. What we have, is what we got. And even these have competition from others right at our necks. Except hip fracture since nobody wants it.
Thermo is a possibility if they can utilize our technology. That is a big IF. Just some Hail Mary’s being thrown out there by management to raise cash. If they did this 10 years ago would have been a home run. Right now, we are down 10-0 in the bottom of the ninth, counts 3 and 2 with 2 out, nobody on. Kept everything all to themselves and here we sit with so little cash they have started to implement cost saving initiatives. But sure, start another product from results on mice. Mind you with them, they could.
A 75L bioreactor is a good size for shots, horrible for manufacturing cells on a commercial scale.